ClinicalTrials.gg
CompletedNCT03805802Updated Oct 22, 2020

Influence of a Liquid Oat Bran Product on Blood Glucose in Patients With Poorly Controlled Type 2 Diabetes

An interventional study of active product and reference product in Diabetes Mellitus, Type 2, Obesity and Overweight, sponsored by Stoffwechselzentrum Rhein - Pfalz. Completed at 1 site in Germany. Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-10-22.

Sponsored by Stoffwechselzentrum Rhein - Pfalz · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
30 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 756 studies in Diabetes Mellitus, Type 2 with a site in Germany — 46 open to participants now, 67 under way, 23 of them phase 3. Diabetes Mellitus, Type 2 · Germany.

Enrollment
580th of 688
34 · median 218
Started
2019
with 25 others
No phase
87 of 756
9 open now
Registered
580th of 756
by date

Among the 756 studies in Diabetes Mellitus, Type 2 with a site in Germany, this one is the 580th largest by enrollment of the 688 interventional ones that give a count, is one of 26 that started in 2019, is one of 87 with no phase, and was the 580th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

46 of the 756 studies in Diabetes Mellitus, Type 2 with a site in Germany are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 30 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 756 studies in Diabetes Mellitus, Type 2 with a site in Germany, or all of them as a file.
02

Study summary

This study evaluates the effects of an ad libitum addition of a high fiber product to the regular diet of type 2 diabetes patients on body weight and blood sugar control. In the first 6 weeks half of the participants will receive the high fiber test product and half a reference product without fiber. After the first 6 weeks both groups will be switched to the high fiber product.

Read the detailed description

It has previously been shown that an increase in the consumption of fiber improves glucose control in type 2 diabetes. In addition, previous pilot studies have shown that a diet solely based on oat flakes can improve insulin sensitivity and glucose control in poorly controlled type 2 diabetes. Recent clinical data indicates, that early hyperglycemia can be normalized by a diet high in fiber. In this controlled pilot study, a food containing liquid oat bran high in fiber will be studied in type 2 diabetes patients with inadequate glucose control that are treated with oral medication or with additional once-daily insulin only against a reference product. 30 patients will be treated with the oat bran product or reference product over a period of 6 weeks in a double blinded approach, hereafter all participants will be switched to the oat bran product. The primary endpoint will be fasting glucose after 6 weeks. Secondary endpoints will be long-term glucose control as measured by HbA1c, self-documented glucose as well as the body weight and body mass index.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Obesity
  • Overweight
  • Metabolic Syndrome

Keywords

  • fiber
  • type 2 diabetes
  • dietary intervention
  • weight loss
  • glucose control
  • obesity
  • overweight
  • metabolic syndrome
  • oats
04

Who can participate

Ages eligible
30 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 Diabetes with inadequate glucose control and a >7,5 and \< 9%
  • Treatment with all oral antidiabetic medication or injectable GLP-1 analogues
  • 28,0-39,9 kg/m²
  • Age 30-70 years

Exclusion criteria

Exclusion Criteria:

  • insulin treatment
  • Psychiatric Disease
  • Acute Infections
  • Alcohol or drug abuse
  • Acute diverticulitis
  • Malignant tumors or hematologic disorders
  • Heart failure III-IV
  • Acute coronary syndrome
  • Chronic kidney disease > Stage 3 (KDOQI)
  • Pregnancy or Lactation
  • Previous bariatric interventions
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    active product

    Once daily ad libitum consumption of one package of the fiber product 6 weeks (blinded phase). Once daily ad libitum consumption of one package of the fiber product 6 weeks (open phase).

    Other: active product

  • Placebo comparator
    reference product

    Once daily ad libitum consumption of one package of placebo during 6 weeks (blinded phase). Once daily ad libitum consumption of one package of the fiber product 6 weeks (open phase).

    Other: active product · Other: reference product

Interventions

  • Otheractive product

    Once daily consumption over the period of the study

    Also known as: LOB, Liquid Oat Bran, High fiber product

  • Otherreference product

    Once daily consumption over the period of the study

    Also known as: placebo food product

06

What researchers measure

Primary outcomes

  1. Fasting glucose

    Change in the concentratino of fasting venous glucose of daily LOB consumption in mg/dl as compared to the change in fasting glucose for the placebo group at 6 weeks.

    Time frame: 6 weeks

Secondary outcomes

  1. Fasting glucose

    Change in the concentratino of fasting venous glucose of daily LOB consumption in mg/dl as compared to the change in fasting glucose for the placebo group at 12 weeks.

    Time frame: 12 weeks

  2. HBA1c

    long-term glucose control as measured by the concentratino of HbA1c concentration in %

    Time frame: 6 weeks

  3. HBA1c

    long-term glucose control as measured by the concentratino of HbA1c concentration in %

    Time frame: 12 weeks

  4. Self-documented glucose

    Self-monitored glucose levels extracted from glucometers as a mean of the previous two weeks before study visits in mg/dl

    Time frame: 6 weeks

  5. Self-documented glucose

    Self-monitored glucose levels extracted from glucometers as a mean of the previous two weeks before study visits in mg/dl

    Time frame: 12 weeks

  6. Weight

    Chenge in body Weight in kg

    Time frame: 6 weeks

  7. Weight

    Chenge in body Weight in kg

    Time frame: 12 weeks

  8. BMI

    Body Mass Index

    Time frame: 6 weeks

  9. BMI

    Body Mass Index

    Time frame: 12 weeks

  10. Lipid metabolism: Serum triglycerides

    Markers of lipid metabolism at 6 weeks: triglycerides (mg/dl)

    Time frame: 6 weeks

  11. Lipid metabolism: Serum triglycerides

    Markers of lipid metabolism at 12 weeks: triglycerides (mg/dl)

    Time frame: 12 weeks

  12. Lipid metabolism: apolipoprotein A (mg/dl)

    Markers of lipid metabolism at 6 weeks: apolipoprotein A (mg/dl)

    Time frame: 6 weeks

  13. Lipid metabolism: apolipoprotein A (mg/dl)

    Markers of lipid metabolism at 12 weeks: apolipoprotein A (mg/dl)

    Time frame: 12 weeks

  14. Lipid metabolism: Apolipoprotein B mg/dl

    Markers of lipid metabolism at 6 weeks: Apolipoprotein B mg/dl

    Time frame: 6 weeks

  15. Lipid metabolism: Apolipoprotein B mg/dl

    Markers of lipid metabolism at 12 weeks: Apolipoprotein B mg/dl

    Time frame: 12 weeks

  16. Lipid metabolism: Apolipoprotein B / Apolipoprotein A ratio

    Metabolism at 6 weeks: Apolipoprotein B mg/dl / Apolipoprotein A mg/dl ratio

    Time frame: 6 weeks

  17. Lipid metabolism: Apolipoprotein B / Apolipoprotein A ratio

    Markers of lipid metabolism at 12 weeks: Apolipoprotein B mg/dl / Apolipoprotein A mg/dl ratio

    Time frame: 12 weeks

  18. Lipid metabolism: HDL-cholesterol

    Markers of lipid metabolism at 6 weeks: HDL-cholesterol mg/dl

    Time frame: 6 weeks

  19. Lipid metabolism: HDL-cholesterol

    Markers of lipid metabolism at 12 weeks: HDL-cholesterol mg/dl

    Time frame: 12 weeks

  20. Lipid metabolism: LDL- cholesterol mg/dl

    Markers of lipid metabolism at 6 weeks: LDL- cholesterol mg/dl

    Time frame: 6 weeks

  21. Lipid metabolism: LDL- cholesterol mg/dl

    Markers of lipid metabolism at 12 weeks: LDL- cholesterol mg/dl

    Time frame: 12 weeks

  22. Microbiome

    Microbiome in faeces samples at 6 weeks

    Time frame: 6 weeks

  23. Microbiome

    Microbiome in faeces samples at 12 weeks

    Time frame: 12 weeks

  24. Inflammation: Il-6

    Markers of inflammation at 6 weeks IL-6 in ng/ml

    Time frame: 6 weeks

  25. Inflammation: hsCRP

    Markers of inflammation at 6 weeks hsCRP mg/l

    Time frame: 6 weeks

  26. Inflammation: Il-6

    Markers of inflammation at 12 weeks IL-6 in ng/ml

    Time frame: 12 weeks

  27. Inflammation: hsCRP

    Markers of inflammation at 12 weeks hsCRP mg/l

    Time frame: 12 weeks

Other outcomes

  1. Systolic lood pressure

    Systolic blood pressure left arm 6 weeks in mm/Hg

    Time frame: 6 weeks

  2. Diastolic blood pressure

    Diastolic blood pressure left arm 6 weeks in mm/Hg

    Time frame: 6 weeks

  3. Systolic blood pressure

    Systolic blood pressure left arm 12 weeks in mm/Hg

    Time frame: 12 weeks

  4. Diastolic blood pressure

    Diastolic blood pressure left arm 12 weeks in mm/Hg

    Time frame: 12 weeks

  5. Waist circumference

    Waist circumference at 6 weeks in cm

    Time frame: 6 weeks

  6. Waist circumference

    Waist circumference at 12 weeks in cm

    Time frame: 12 weeks

07

Study locations

1 site
  • Stoffwechselzentrum Rhein-Pfalz
    Mannheim, Baden-Württemberg 68163, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Apr 2020, 13 months.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 13 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2019
First posted
Jan 16, 2019
StartActual
Feb 4, 2019
Primary completionActual
Apr 1, 2020
CompletionActual
Apr 1, 2020
Last update
Oct 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03805802
Lead sponsor
Stoffwechselzentrum Rhein - Pfalz
Collaborators
Glucanova AB
Responsible party
Dr. Per Humpert (Director of Stoffwechselzentrum Rhein - Pfalz, Stoffwechselzentrum Rhein - Pfalz) — Principal investigator
First posted
Jan 16, 2019
Start date
Feb 4, 2019
Primary completion
Apr 1, 2020
Completion
Apr 1, 2020
Last update
Oct 22, 2020

Study contacts

Per M Humpert, M. D.
principal investigator · Director of Stoffwechselzentrum Rhein-Pfalz

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion